Action to achieve smoke-free homes- an exploration of experts' views

Background: Smoking in the home is the major cause of exposure to second-hand smoke in children in the UK, particularly those living in low income households which have fewer restrictions on smoking in the home. Reducing children's exposure to second-hand smoke is an important public health and inequalities issue. Drawing on findings from a qualitative Scottish study, this paper identifies key issues and challenges that need to be considered when developing action to promote smoke-free homes at the national and local level. Methods: Two panels of tobacco control experts (local and national) from Scotland considered the implications of the findings from a qualitative study of smokers and non-smokers (who were interviewed about smoking in the home), for future action on reducing smoking in the home. Results: Several key themes emerged through the expert panel discussions. These related to: improving knowledge about SHS among carers and professionals; the goal and approach of future interventions (incremental/harm reduction or total restrictions); the complexity of the interventions; and issues around protecting children. Conclusion: The expert panels were very aware of the sensitivities around the boundary between the 'private' home and public health interventions; but also the lack of evidence on the relative effectiveness of specific individual and community approaches on increasing restrictions on smoking in the home. Future action on smoke-free homes needs to consider and address these complexities. In particular health professionals and other key stakeholders need appropriate training on the issues around smoking in the home and how to address these, as well as for more research to evaluate interventions and develop a more robust evidence base to inform effective action on this issue

Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)

Abstract Federal regulatory agencies such as the United States Food and Drug Administration review pharmacological evidence to ensure the safety and efficacy of new and repurposed pharmaceuticals prior to market approval. The discussions, disagreements and procedural decisions contained within such reviews offer unique insight into a pharmaceutical's strengths, weaknesses and opportunities, yet are often overlooked as a significant source of pharmacological information for research and development. To highlight the value of such resources, we present a case study on Entresto, a first‐in‐class angiotensin receptor‐neprilysin inhibitor for the treatment of heart failure with reduced ejection fraction, and explore the regulatory rationale underlying its market approval. Using information extracted from Entresto's online approval package at Drugs@FDA, we explore some of the procedural complexities underlying market approval of new pharmaceuticals, discuss the broad pharmacological implications contained within regulatory agency grey literature, and highlight opportunities for future therapeutic development

Impact of Acute Circuit Training on Irisin in Younger and Older Overweight Adults

Studies show aerobic exercise increases irisin and leads to health benefits. The impact of circuit training (CT) on irisin in overweight younger and older adults is unknown. The objectives were to determine whether, during an acute bout of CT, changes in irisin differed between overweight younger and older adults, and if irisin is associated with body composition, fitness level, or muscle strength. Inactive, overweight adults aged between 19-35 (25.9 5.0; n=15) and 60-75 years old (67.7 4.1; n=14) participated in this study. The primary exposure variable was an acute bout of CT (12-15 repetitions; 65-70% of 1-repetition maximum; 3 loops). The primary outcome measure was the concentration of irisin determined by ELISA before, during, and after exercise. Repeated measures analyses showed no effect of time on irisin levels during acute CT, and no interaction effect between age and time (p >0.05). No associations were observed between changes in irisin and body composition, fitness, or strength (p >0.05). In conclusion, acute CT doesn’t increase irisin in overweight individuals, nor is irisin associated with the measured outcomes. Further studies are needed to elucidate the release of irisin by different types of exercise across the lifespan. NCT03715088 NOVELTY: • Younger and older adults show a similar irisin response to an acute bout of circuit training. • Irisin response is not associated with measures of body composition, cardiorespiratory fitness, nor muscle strength.The accepted manuscript in pdf format is listed with the files at the bottom of this page. The presentation of the authors' names and (or) special characters in the title of the manuscript may differ slightly between what is listed on this page and what is listed in the pdf file of the accepted manuscript; that in the pdf file of the accepted manuscript is what was submitted by the author